BRPI0608205B8 - derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dor - Google Patents
derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dorInfo
- Publication number
- BRPI0608205B8 BRPI0608205B8 BRPI0608205A BRPI0608205A BRPI0608205B8 BR PI0608205 B8 BRPI0608205 B8 BR PI0608205B8 BR PI0608205 A BRPI0608205 A BR PI0608205A BR PI0608205 A BRPI0608205 A BR PI0608205A BR PI0608205 B8 BRPI0608205 B8 BR PI0608205B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treatment
- pain
- urinary incontinence
- urinary
- Prior art date
Links
- 206010036018 Pollakiuria Diseases 0.000 title abstract 4
- 206010046543 Urinary incontinence Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000002193 Pain Diseases 0.000 title abstract 2
- 206010020853 Hypertonic bladder Diseases 0.000 title 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 title 1
- 208000020629 overactive bladder Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000022934 urinary frequency Diseases 0.000 title 1
- 230000036318 urination frequency Effects 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 101150042613 FA2H gene Proteins 0.000 abstract 2
- 101150008770 FAAH gene Proteins 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 abstract 1
- 230000003574 anti-allodynic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005040197 | 2005-02-17 | ||
| JP2005303065 | 2005-10-18 | ||
| PCT/JP2006/302698 WO2006088075A1 (ja) | 2005-02-17 | 2006-02-16 | ピリジル 非芳香族含窒素ヘテロ環－１－カルボン酸エステル誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0608205A2 BRPI0608205A2 (pt) | 2009-12-01 |
| BRPI0608205B1 BRPI0608205B1 (pt) | 2019-02-05 |
| BRPI0608205B8 true BRPI0608205B8 (pt) | 2021-05-25 |
Family
ID=36916476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0608205A BRPI0608205B8 (pt) | 2005-02-17 | 2006-02-16 | derivado heterocíclico-1-carboxilato de piridila não-aromático nitrogenado, composição farmacêutica e uso do dito composto para o tratamento de frequência urinária, incontinência urinária, bexiga hiperativa e dor |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7919495B2 (enExample) |
| EP (2) | EP1849773B1 (enExample) |
| JP (1) | JP4702361B2 (enExample) |
| KR (3) | KR101063585B1 (enExample) |
| CN (1) | CN101160287B (enExample) |
| AU (3) | AU2006215080B2 (enExample) |
| BR (1) | BRPI0608205B8 (enExample) |
| CA (1) | CA2598294C (enExample) |
| CY (2) | CY1114709T1 (enExample) |
| DK (2) | DK2607362T3 (enExample) |
| ES (2) | ES2433290T3 (enExample) |
| IL (1) | IL184998A (enExample) |
| MX (1) | MX2007010076A (enExample) |
| NO (1) | NO20074697L (enExample) |
| PL (2) | PL1849773T3 (enExample) |
| PT (2) | PT1849773E (enExample) |
| RU (3) | RU2408580C2 (enExample) |
| SI (2) | SI1849773T1 (enExample) |
| TW (3) | TW200640864A (enExample) |
| WO (1) | WO2006088075A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| JP2008545010A (ja) * | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Ｇタンパク質共役受容体アゴニスト |
| AU2006264649A1 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| US7541359B2 (en) | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| WO2007098086A2 (en) * | 2006-02-17 | 2007-08-30 | Avalon Pharmaceuticals | Hydroxypiperidine derivatives and uses thereof |
| JPWO2008023720A1 (ja) * | 2006-08-23 | 2010-01-14 | アステラス製薬株式会社 | ウレア化合物又はその塩 |
| GEP20125425B (en) | 2006-10-18 | 2012-03-26 | Pfizer Prod Inc | Biaryl ether urea compounds |
| CA2687931C (en) | 2007-05-31 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
| BRPI0815591B8 (pt) | 2007-08-22 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, e, uso de um composto. |
| BRPI0911118A2 (pt) * | 2008-04-07 | 2015-10-06 | Irm Llc | composto e compisições como moduladores de atividade de gpr119 |
| US20090325964A1 (en) * | 2008-05-23 | 2009-12-31 | Wyeth | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression |
| TWI434842B (zh) * | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| JPWO2010053120A1 (ja) | 2008-11-06 | 2012-04-05 | アステラス製薬株式会社 | カルバメート化合物又はその塩 |
| ES2551557T3 (es) | 2008-12-19 | 2015-11-19 | Boehringer Ingelheim International Gmbh | Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| PL2513093T3 (pl) | 2009-12-17 | 2015-03-31 | Centrexion Therapeutics Corp | Nowi antagoniści receptora CCR2 i ich zastosowanie |
| US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
| EP2531500B1 (en) | 2010-02-05 | 2018-01-24 | Merck Patent GmbH | Hetaryl-[1,8]naphthyridine derivatives |
| AU2011218491C1 (en) | 2010-02-18 | 2015-05-14 | Astrazeneca Ab | Processes for making cyclopropyl amide derivatives and intermediates associated therewith |
| WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
| JP2013147430A (ja) * | 2010-04-28 | 2013-08-01 | Astellas Pharma Inc | 夜間頻尿の予防又は治療剤 |
| TW201206440A (en) * | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
| EP2569295B1 (en) | 2010-05-12 | 2014-11-19 | Boehringer Ingelheim International GmbH | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| EP2571870B1 (en) | 2010-05-17 | 2015-01-21 | Boehringer Ingelheim International GmbH | Ccr2 antagonists and uses thereof |
| US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
| JP5721242B2 (ja) | 2010-06-01 | 2015-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２アンタゴニスト |
| JP5786258B2 (ja) | 2011-07-15 | 2015-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規かつ選択的なｃｃｒ２拮抗薬 |
| CA2879726A1 (en) * | 2012-07-24 | 2014-01-30 | Bial- Portela & Ca, S.A. | Urea compounds and their use as enzyme inhibitors |
| DE102012018115A1 (de) | 2012-09-13 | 2014-03-13 | Matthias Lehr | Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase |
| GB201218084D0 (en) * | 2012-10-09 | 2012-11-21 | Univ Aston | Novel compounds and methods for use in medicine |
| HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| DE102013016573A1 (de) | 2013-10-04 | 2015-04-09 | Matthias Lehr | 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung |
| MA41168A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Nouveaux composés antibactériens |
| MX383744B (es) | 2015-07-02 | 2025-03-14 | Centrexion Therapeutics Corp | Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona. |
| PT3595665T (pt) | 2017-03-13 | 2024-11-21 | Lundbeck La Jolla Research Center Inc | Inibidores duplos de magl e faah |
| SG10201802129QA (en) * | 2017-07-05 | 2019-02-27 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| EP3737361A4 (en) * | 2018-01-11 | 2021-08-25 | Centaurus Therapeutics | INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR THE TREATMENT OF DISEASES |
| ES2993173T3 (en) * | 2018-09-13 | 2024-12-23 | Celgene Corp | Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1-carboxylate, compositions and methods of use thereof |
| CA3127590A1 (en) * | 2019-01-28 | 2020-08-06 | Mitochondria Emotion, Inc. | Mitofusin activators and methods of use thereof |
| CN115279359A (zh) | 2019-11-29 | 2022-11-01 | 速通医疗公司 | 新型拟甲状腺素药 |
| EP4168384A4 (en) | 2020-06-17 | 2024-07-10 | Autobahn Therapeutics, Inc. | THYROMIMETICS |
| EP4167986A4 (en) | 2020-06-17 | 2024-11-20 | Autobahn Therapeutics, Inc. | THYROMIMETICS |
| AU2022271304A1 (en) | 2021-05-06 | 2023-11-23 | Autobahn Therapeutics, Inc. | Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors |
| WO2024072930A1 (en) * | 2022-09-30 | 2024-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200462B (enExample) * | 1990-09-27 | 1993-02-21 | Hoechst Roussel Pharma | |
| US5744485A (en) * | 1994-03-25 | 1998-04-28 | Vertex Pharmaceuticals Incorporated | Carbamates and ureas as modifiers of multi-drug resistance |
| SK282252B6 (sk) * | 1995-01-11 | 2001-12-03 | Samjin Pharmaceutical Co., Ltd. | Piperazínové deriváty a farmaceutický prostriedok s ich obsahom |
| EP0850222B1 (en) * | 1996-06-29 | 2003-05-28 | Samjin Pharmaceutical Co., Ltd. | Piperazine derivatives and process for the preparation thereof |
| US5870472A (en) * | 1996-11-12 | 1999-02-09 | General Instrument Corporation | Dynamic relocation of the service data channel |
| US5780484A (en) * | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
| YU47600A (sh) | 1998-01-27 | 2002-09-19 | Aventis Pharmaceuticals Products Inc. | SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa |
| PL350884A1 (en) | 1999-04-01 | 2003-02-10 | Pfizer Prod Inc | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| KR20020087041A (ko) | 1999-07-28 | 2002-11-21 | 아벤티스 파마슈티칼스 프로덕츠 인크. | 치환된 옥소아자헤테로사이클릴 화합물 |
| KR20030059290A (ko) | 2000-11-30 | 2003-07-07 | 화이자 프로덕츠 인코포레이티드 | Ｇａｂａ 작용제 및 소르비톨 데하이드로게나제 억제제의혼합물 |
| DE60216830T2 (de) | 2001-02-06 | 2007-06-14 | Pfizer Products Inc., Groton | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen |
| BR0214967A (pt) | 2001-12-14 | 2005-05-10 | Novo Nordisk As | Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente |
| WO2003055848A2 (en) | 2001-12-26 | 2003-07-10 | Bayer Healthcare Ag | Urea derivatives as vr1- antagonists |
| JP2003192659A (ja) | 2001-12-26 | 2003-07-09 | Bayer Ag | フェニル尿素誘導体 |
| PL373970A1 (en) | 2002-02-08 | 2005-09-19 | Bristol-Myers Squibb Company | (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| FR2843964B1 (fr) | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
| EP1558591B1 (en) * | 2002-10-07 | 2014-05-07 | The Regents of The University of California | Modulation of anxiety through blockade of anandamide hydrolysis |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| JP2006527212A (ja) | 2003-06-12 | 2006-11-30 | ノボ ノルディスク アクティーゼルスカブ | ホルモン感受性リパーゼの阻害剤として使用するための、置換ピペラジンカルバメート |
| BRPI0410657A (pt) | 2003-06-12 | 2006-06-20 | Novo Nordisk As | composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto |
| EP1636207A1 (en) | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| FR2865205B1 (fr) | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866888B1 (fr) | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
| FR2866884B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
| EP1882684B1 (en) * | 2005-05-19 | 2014-12-10 | Astellas Pharma Inc. | Pyrrolidine derivative or salt thereof |
-
2006
- 2006-02-16 MX MX2007010076A patent/MX2007010076A/es active IP Right Grant
- 2006-02-16 RU RU2009121774/04A patent/RU2408580C2/ru active
- 2006-02-16 PL PL06713839T patent/PL1849773T3/pl unknown
- 2006-02-16 EP EP06713839.6A patent/EP1849773B1/en not_active Expired - Lifetime
- 2006-02-16 KR KR1020097011570A patent/KR101063585B1/ko not_active Expired - Fee Related
- 2006-02-16 TW TW095105236A patent/TW200640864A/zh not_active IP Right Cessation
- 2006-02-16 AU AU2006215080A patent/AU2006215080B2/en not_active Ceased
- 2006-02-16 CA CA2598294A patent/CA2598294C/en not_active Expired - Lifetime
- 2006-02-16 KR KR1020097011569A patent/KR101065979B1/ko not_active Expired - Fee Related
- 2006-02-16 ES ES06713839T patent/ES2433290T3/es not_active Expired - Lifetime
- 2006-02-16 PT PT67138396T patent/PT1849773E/pt unknown
- 2006-02-16 SI SI200631681T patent/SI1849773T1/sl unknown
- 2006-02-16 JP JP2007503689A patent/JP4702361B2/ja not_active Expired - Lifetime
- 2006-02-16 TW TW098121395A patent/TWI385164B/zh not_active IP Right Cessation
- 2006-02-16 ES ES13160373.0T patent/ES2528674T3/es not_active Expired - Lifetime
- 2006-02-16 KR KR1020077020924A patent/KR101063663B1/ko not_active Expired - Fee Related
- 2006-02-16 DK DK13160373.0T patent/DK2607362T3/en active
- 2006-02-16 SI SI200631896T patent/SI2607362T1/sl unknown
- 2006-02-16 BR BRPI0608205A patent/BRPI0608205B8/pt active IP Right Grant
- 2006-02-16 US US11/816,508 patent/US7919495B2/en active Active
- 2006-02-16 WO PCT/JP2006/302698 patent/WO2006088075A1/ja not_active Ceased
- 2006-02-16 RU RU2009121775/04A patent/RU2408581C2/ru active
- 2006-02-16 EP EP13160373.0A patent/EP2607362B1/en not_active Expired - Lifetime
- 2006-02-16 PT PT13160373T patent/PT2607362E/pt unknown
- 2006-02-16 DK DK06713839.6T patent/DK1849773T3/da active
- 2006-02-16 CN CN200680004214XA patent/CN101160287B/zh not_active Expired - Lifetime
- 2006-02-16 PL PL13160373T patent/PL2607362T3/pl unknown
- 2006-02-16 RU RU2007134441/04A patent/RU2376289C2/ru active
- 2006-02-16 TW TW098121399A patent/TWI385152B/zh not_active IP Right Cessation
-
2007
- 2007-08-02 IL IL184998A patent/IL184998A/en not_active IP Right Cessation
- 2007-09-14 NO NO20074697A patent/NO20074697L/no not_active Application Discontinuation
-
2009
- 2009-08-19 US US12/543,690 patent/US7919494B2/en not_active Expired - Lifetime
- 2009-08-19 US US12/543,659 patent/US7915261B2/en not_active Expired - Lifetime
-
2010
- 2010-06-04 AU AU2010202347A patent/AU2010202347B2/en not_active Ceased
- 2010-06-04 AU AU2010202348A patent/AU2010202348B2/en not_active Ceased
-
2013
- 2013-12-04 CY CY20131101099T patent/CY1114709T1/el unknown
-
2015
- 2015-02-25 CY CY20151100193T patent/CY1116348T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0608205A2 (pt) | derivado heterocìclico-1-carboxilato de piridila não-aromático nitrogenado | |
| Crosson et al. | Inhibition of histone deacetylase protects the retina from ischemic injury | |
| BRPI0610321B8 (pt) | imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica | |
| Kosuge | Neuroprotective mechanisms of S-allyl-L-cysteine in neurological disease | |
| DE602007004618D1 (de) | Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren | |
| AR076400A1 (es) | Formulaciones liquidas de sales de 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazina, uso, la sal y recipiente | |
| BR0209957A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
| NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
| BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
| BR0315988A (pt) | Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos | |
| BR112014006763A2 (pt) | n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1 | |
| TW200635912A (en) | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase | |
| NO20055216D0 (no) | Nye hydroksamater som terapeutiske midler | |
| BRPI0410563B8 (pt) | compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas | |
| BR0008958A (pt) | Inibidores de reabsorção de monoamina para otratamento de distúrbios do snc | |
| BRPI0921692A2 (pt) | composto carbamato ou o sal do mesmo | |
| BRPI0515931A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos | |
| BRPI0618239A2 (pt) | uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusico | |
| BR0312232A (pt) | Inibidores de caspases e seus usos | |
| BRPI0411936A (pt) | composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade | |
| BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
| DK1296972T3 (da) | Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer | |
| Bellino et al. | Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study | |
| BR0308108A (pt) | Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade | |
| CL2016001707A1 (es) | Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/02/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |